Prostate tumour biomarkers in metastatic disease
Poster Session 76

Monday 23 March
14:00 - 15:30

Location: Grey Area, RAI Auditorium
Chairs: S. Perner, Luebeck (DE)
        K.A. Tasken, Oslo (NO)
        To be confirmed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1044

Longitudinal analysis of personal DNA methylome patterns in metastatic prostate cancer

By: Silva R.S ¹, Moran B.M ², Gallagher W.G ³, Brennan D.B. ², Perry A. ¹
¹University College Dublin, Dept. of Biology and Environmental Science, Dublin, Ireland,
²University College Dublin, Dept. of Medicine, Dublin, Ireland,
³University College Dublin, Dept. of Biomolecular and Biomedical Science, Dublin, Ireland

* 1045

Can Prostatype® improve prognostic evaluation for metastasis and death in prostate cancer, a validation study

By: Saemundsson A. ¹, Ahlgren G. ¹, Meisgen F. ², Cao R. ²
¹Skåne University Hospital, Dept. of Urology, Malmö, Sweden,
²Chundsell Medcals AB, Dept. of QC, Stockholm, Sweden

* 1046

The combination of size-based separation and selection-free technology provides higher CTC detection sensitivity than either method alone in patients with metastatic prostate cancer

By: Dong L. ¹, Zhang Z. ¹, Smith K. ¹, Kuczler M. ¹, Reyes D. ¹, Amend S.R. ¹, Cho Y.K. ², Xue W. ³, Pienta K.J. ¹
¹Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America,
²School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), Dept. of Biomedical Engineering, Ulsan, South Korea,
³Shanghai Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China

1047

Differences in genomic profiles between chinese and caucasian castration-resistant prostate cancer

By: Ke L. ¹, Yunhua M. ², Wenzhuan X. ³, Mengli H. ³, Chan G. ³, Dejuan W. ⁴, Jianguang Q. ⁴
¹The Third Affiliated Hospital Sun Yat-sen University, Dept. of Urinary Surgery,
1048  **Prevalence of mutations in a comprehensive DNA damage repair gene panel in Chinese prostate cancer patients**  
By: Wei Y.1, Wu J.1, Zhu Y.1, Ye D.1  
Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

1049  **Methylation can regulate the expression of PD-L1 in Small cell prostate cancer**  
By: Sun Y.1, Wei Q.1, Huang J.2, Yang L.1  
1West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China, 2Duke University, Dept. of Pathology, Durham, United States of America

1050  **Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer**  
By: Hatakeyama S.1, Yoneyama T.1, Tobisawa Y.1, Yamamoto H.1, Imai A.1, Yoneyama T.2, Hashimoto Y.2, Ohyama C.2  
Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan

1051  **Serum levels of sex hormone binding globulin are not predictive of poorly differentiated prostate cancer or advanced prostate cancer: Results from a radical prostatectomy cohort**  
By: De Nunzio C.1, Brassetti A.1, Cancrini F.1, Tema G.1, Sica A.2, Bellangino M.2, D’annunzio S.3, Sarchi L.3, Voglino O.A.3, Lombardo R.3, Tubaro A.3  
Sant’Andrea Hospital, Dept. of Urology, Rome, Italy

1052  **Relationship between specific embryonic antigen-4 expression and the androgen dependency of cancer cells and tumour-infiltrating cells in prostate cancer**  
By: Shida Y.1, Miyata Y.1, Hakariya T.1, Nakamura Y.1, Matsuo T.1, Ohba K.1, Taima T.2, Ito A.2, Suda T.3, Hakomori S-I.4, Saito S.3, Sakai H.1  
1Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, 2Tohoku University Graduate School of Medicine, Dept. of Urology, Miyagi, Japan, 3University of the Ryukyus, Dept. of Urology, Okinawa, Japan, 4University of Washington, Dept. of Pathobiology and Global Health, Seattle, United States of America

1053  **Oncogenic role of PGC1α in prostate cancer**  
By: Yang Z.M.1, Teramoto Y.1, Miyamoto H.1  
University of Rochester Medical Center, Dept. of Pathology and Laboratory Medicine, Rochester, United States of America
Master Transcription Regulators (MTRs) previously associated with breast cancer used to generate a prognostic model for biochemical recurrence after radical prostatectomy

By: Teltsh O. 1, Barron S. 2, Gallagher W.M. 3, Watson R.W. 1
1University Collage Dublin, UCD School of Medicine, Dublin, Ireland, 2OncoMark Ltd, -, Dublin, Ireland, 3University Collage Dublin, UCD School of Biomolecular and Biomedical Science, Dublin, Ireland

Summary
To be confirmed